Colorectal Cancer

MADRID — Remarkable. Highly meaningful. Monumental.

From updates in colorectal cancer screening to developments in screening methods, Healio has been at the forefront of coverage for gastrointestinal cancer in 2023 – but has the important news made its way to your patients?

Topline findings from the eAArly DETECT trial showed Mainz Biomed’s novel mRNA biomarkers boasted a sensitivity and specificity of 97% for detection of colorectal cancer, and an 82% sensitivity for advanced adenomas detection.

In this episode, host Shikha Jain, MD, speaks with Erica Barnell, MD, PhD, about Geneoscopy’s non-invasive screening and early detection technology, helping improve patient compliance for gastrointestinal health and more.

Among patients with negative fecal immunochemical tests, those with values in the upper range demonstrated higher risk for advanced neoplasia vs. those in the lower range, according to data in Annals of Internal Medicine.

A risk-advancement period approach using sex and polygenic risk score helped identify starting ages for colorectal cancer screening, with men reaching an equivalent risk for CRC occurrence and mortality at a younger age than women.

The ColoSense multitarget stool RNA test demonstrated high sensitivity for detection of colorectal cancer and advanced adenoma, notably in individuals aged 45 to 49 years, according to data in JAMA.

Older adults who were given personalized information about benefits and harms of colorectal cancer screening were more likely to receive screening orders that aligned with benefit, reducing overall use of screening, researchers reported.

Glucagon-like peptide 1 receptor agonists were associated with a reduced risk for colorectal cancer among patients with type 2 diabetes, regardless of weight status, compared with other antidiabetics, according to research.

Diagnostic test completion for early age-onset colorectal cancer is low among U.S. veterans presenting with iron-deficiency anemia or hematochezia, with women and Black and Hispanic veterans less likely to undergo follow-up testing.